Uwe Thuss

Department Of MR And CT Contrast Media Research And Research And Pre Clinical Statistics Group, Müllerstraße 178
Berlin, BE 13353, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy.

Gadolinium Presence in Rat Skin: Assessment of Histopathologic Changes Associated with Small Fiber Neuropathy.

Journal: Radiology

Published: January 16, 2024

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

Journal: British journal of clinical pharmacology

Published: October 12, 2021

Pharmacokinetics, Safety, and Tolerability of the α2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects.

Pharmacokinetics, Safety, and Tolerability of the α2C -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects.

Journal: Clinical pharmacology in drug development

Published: May 20, 2021

Absorption, distribution, metabolism and excretion of molidustat in healthy participants.

Absorption, distribution, metabolism and excretion of molidustat in healthy participants.

Journal: Basic & clinical pharmacology & toxicology

Published: January 17, 2020

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Journal: International journal of cancer

Published: September 07, 2018

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.

Journal: Clinical pharmacology in drug development

Published: March 07, 2018

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.

Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.

Journal: ChemMedChem

Published: December 14, 2017

First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.

First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.

Journal: British journal of clinical pharmacology

Published: September 05, 2017

Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.

Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.

Journal: Drug testing and analysis

Published: March 22, 2016

Determination of nifurtimox in dog plasma by stable-isotope dilution LC-MS/MS.

Determination of nifurtimox in dog plasma by stable-isotope dilution LC-MS/MS.

Journal: Bioanalysis

Published: November 14, 2015

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.

Journal: PloS one

Published: June 25, 2014

Showing 1-11 of 11

Last Updated: 09/26/2026